

February 20, 2026

Notice Regarding Investment in LTL Pharma Co., Ltd., a Domestic Pharmaceutical Manufacturer in Japan

Oji Holdings Corporation (CEO: Hiroyuki Isono, Head Office: Chuo-ku, Tokyo) hereby announces that Oji Holdings Corporation and the Unison Capital Partners VI, LPS. have acquired all shares of LTL Pharma Co., Ltd. (President: Tetsuo Ito, Head Office: Shinjuku-ku, Tokyo; “LTL”), a domestic manufacturer and seller of prescription pharmaceuticals, under the umbrella of the Unison Capital Inc. (President: Tatsuya Hayashi, Head office: Chiyoda-ku, Tokyo; “Unison”), as of February 20, 2026, through a special purpose company jointly funded by Oji Holdings Corporation and the Unison Capital Partners VI, LPS. As a result of this acquisition, LTL has become an affiliate of Oji Holdings Corporation.

Under its “Medium-Term Management Plan 2027”, Oji Group is designating the wood-biomass business as a core strategic area, as part of the transformation of its business portfolio. Oji Pharma Co., Ltd. (“Oji Pharma”, President: Kotaro Ishikawa, Head Office: Chuo-ku, Tokyo), wholly owned subsidiary, is conducting R&D on nature-derived animal and human pharmaceuticals.

Oji Pharma’s wood-derived material, sulfated hemicellulose (generic name: Pentosan Polysulfate Sodium (PPS)), obtained approval in Australia as an active pharmaceutical ingredient (API) for veterinary use in 2025. Other pipeline products are also advancing toward commercialization—for example, the generic version of betaine for homocystinuria received approval in Japan in February 2026.

Founded in 2016, LTL is dedicated to reliable and continuous deliver long-life pharmaceuticals—drugs whose reimbursement prices have been maintained over extended periods—originally developed by pioneer manufacturers. Leveraging an efficient business model, LTL allocates substantial management resources to safety and quality assurance, establishing itself as a trusted supplier of long-listed prescription medicines. Through this investment, Oji Holdings will leverage LTL’s specialized expertise and operational know-how to accelerate the launch of Oji Pharma’s biomass-derived pharmaceutical business and further strengthen its wood-biomass initiatives.

【LTL Overview】

Company Name	LTL Pharma Co., Ltd.
Head Office Location	Shinjuku-ku, Tokyo
Business	Manufacturing, marketing and import/export of ethical drugs

Since LTL’s inception, Unison has held all of its shares, has been actively involved in the company’s business operations, and continuously supported its growth as a steadfast partner.

Oji Group will continue to contribute to society in the medical and healthcare fields, based on its nature-positive management approach.

【Impact on Financial Results in the Current Fiscal Year】

This matter will have a minor impact on the forecast of financial results for the fiscal year ending March 2026.

Contact

Business Planning Department,
Oji Pharma Co., Ltd.

Phone: +81-3-3520-9888 E-mail: ojipharma-info@oji-gr.com

Public Relations and Investor Relations Department, Corporate Governance Division,

Oji Holdings Corporation <https://www.ojiholdings.co.jp/en/>

Phone: +81-3-3563-4523 E-mail: oji-holdings@oji-gr.com